This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Netarsudil, a Rho kinase (ROCK) inhibitor, targets the underlying pathophysiology of elevated IOP (intraocular pressure), increased trabecular outflow resistance, and thereby increases trabecular outflow and reduces IOP (1):

  • distinct mechanism of action of netarsudil has been demonstrated to involve increasing trabecular outflow by decreasing actomyocin-driven cellular contraction and reducing production of extracellular matrix proteins

Latanoprost, the most commonly prescribed prostaglandin analogue, has a complementary mechanism of action, lowering IOP by increasing uveoscleral outflow (1).

NICE states that (2):

  • latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not reduced IOP enough, only if:
    • they have then tried a fixed-dose combination treatment and it has not reduced IOP enough, or
    • a fixed-dose combination treatment containing beta-blockers is unsuitable

Reference:

  1. Asrani S et al. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2. Adv Ther. 2020 Apr;37(4):1620-1631.
  2. NICE (October 2024). Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.